Using hospital‐linked UK primary care records (Clinical Practice Research Datalink; 2004–2020), we identified 7084 people with a pancreatic condition (acute pancreatitis, chronic pancreatitis, pancreatic cancer and haemochromatosis) preceding diabetes diagnosis (type 3c cohort), initiating oral glucose‐lowering therapy (metformin, sulphonylureas, SGLT2‐inhibitors, DPP4‐inhibitors or thiazolidinediones), and without concurrent insulin treatment. Here, SLC5A2 is linked to pancreatic neoplasm.